Bedford, MA-based Homology Medicines (Pending:FIXX) is set for its IPO of ~6.7M shares of common stock at $14 - 16.
The company develops genetic medicines based on its proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely deliver gene therapies or nuclease-free gene editing modalities across a broad range of genetic disorders. The company says its value proposition is precise gene correction at therapeutic levels without the unwanted on- and off-target effects.
Lead candidate is Phase 1/2-stage HMI-102, a gene therapy for phenylketonuria (PKU).

